The Life Sciences Report

Biopharma Releases New Antibiotic in the US for Complicated UTIs
Source: Streetwise Reports  (7/24/18)
A LifeSci Capital report reviewed why uptake of a drug that targets complicated urinary tract infections could be significant and swift. More >

Australian Regenerative Medicine Firm 'Lands a Great Partner in China'
Source: Streetwise Reports  (7/22/18)
A Maxim Group report reviewed the deal between the two companies. More >

Healthcare Tech Company Receives US Patent
Source: Streetwise Reports  (7/19/18)
The U.S Patent and Trademark Office has granted the allowance to a technology company whose platform allows healthcare organizations to buy, sell and trade equipment and supplies. More >

Cannabis Firm Targets Sexual Health and Wellness
Source: Ron Struthers for Streetwise Reports  (7/17/18)
California, with nearly 40 million residents, offers a cannabis market as large as the whole of Canada, says Ron Struthers, editor of Struthers Resource Stock Report. He believes that companies that have a road into California will gain early traction, and he profiles one such firm. More >

Cell Therapy Company and Chinese Firm Sign Marketing Deal
Source: Streetwise Reports  (7/15/18)
This biotech, in Phase 1 development of regenerative technologies addressing skin and orthopedic indications, has finalized a commercialization deal with YOFOTO. More >

Preclinical Data for Alzheimer's Therapy to Be Presented at AAIC
Source: Streetwise Reports  (7/11/18)
A poster outlining data from this company's lead candidate, which targets toxic oligomers identified as a potential cause of Alzheimer's disease, will be presented at the Alzheimer's Association International Conference (AAIC). More >

Three Companies Poised to Benefit from Proposed Medicare Home Health Monitoring Change
Source: Streetwise Reports  (7/10/18)
A proposed rule change would allow Medicare to reimburse home health agencies for remote patient monitoring, providing an opportunity for health technology companies. More >

Study Shows Biopharma's Lead Drug Mediates T Cell Tumor Infiltration
Source: Streetwise Reports  (7/10/18)
An Echelon Wealth Partners report discussed this firm's stock performance and how a recent clinical trial update impacted it. More >

Coverage Initiated on 'True Original' Using RNAi to Enhance Cancer Immunotherapy
Source: Streetwise Reports  (7/10/18)
An H.C. Wainwright & Co. report outlined the thesis for investing in this emerging biotech. More >

EpiPen Rival Lands Major Partner
Source: Streetwise Reports  (7/3/18)
An H.C. Wainwright & Co. report explains the deal, which concerns a new single-dose epinephrine injection for severe allergic reactions. More >

Target Price Increased on Biotech After Q2/18 Revenue Record, Beat
Source: Streetwise Reports  (7/3/18)
A Maxim Group report explained the likely reasons behind revenue growth for the firm, which produces media used in development of cell therapies. More >

Coverage Initiated on Biopharma with 'Opioid Sparing Solution for Post-Op Pain'
Source: Streetwise Reports  (6/27/18)
An H.C. Wainwright & Co. report highlighted the advantages, status and potential of this lead asset. More >

Immunotherapy Firm's Triple Combination Trial for Glioblastoma Sees First Patient Dosed
Source: Streetwise Reports  (6/27/18)
A Maxim Group note discussed the latest clinical endeavor involving a three-pronged approach targeting glioblastoma. More >

Candidates Targeting Parkinson's Disease and ALS Advance in Discovery Phase
Source: Streetwise Reports  (6/26/18)
This precision medicine company, focused on neurodegenerative diseases, has selected antibody candidates to advance into the final phase of discovery. More >

Agreement Facilitates Progress Toward Medical Device Approvals
Source: Streetwise Reports  (6/20/18)
This medical device company enters a partnership to provide quality and regulatory services. More >

Coverage Initiated on Immunotherapy Developer with Phase 3 Lead Asset
Source: Streetwise Reports  (6/20/18)
A B. Riley FBR report provided an overview of this life sciences firm. More >

Transfusion Medicine Biotech Hits Target on Road to Commercialization
Source: Streetwise Reports  (6/20/18)
A BTIG report reviewed the news announced by this supplier of blood grouping reagents and control products. More >

Biotech Targeting Alzheimer's Disease Advances Toward Phase 1
Source: Streetwise Reports  (6/13/18)
Having secured a manufacturing partner for its proprietary antibody candidate, this precision medicine company charts progress toward a Phase 1 trial in Alzheimer's disease. More >

Biotech Releases 'Unequivocally Positive' Topline NASH Study Results
Source: Streetwise Reports  (6/13/18)
An H.C. Wainwright & Co. report relayed the highlights of the new trial data from this Israel-based firm. More >

Mobile Health Platform Firm Signs Deal That Will Increase Pace of Onboarding Patients
Source: Streetwise Reports  (6/6/18)
A technology company that develops mobile health and telemedicine platforms for community-based healthcare has raised money, made a deal that will accelerate the number of patients it adds every month, and is breaking through its hardware logjam. More >

Biotech Consolidates Shares in Preparation for NASDAQ Listing
Source: Streetwise Reports  (6/5/18)
A Canaccord Genuity analyst provided an update on this late-stage Canadian life sciences firm targeting metastatic breast cancer. More >

Coverage Initiated on Developer of Women's Reproductive Health Products
Source: Streetwise Reports  (5/30/18)
A ROTH Capital Partners research report outlined the key drivers of the investment thesis for this firm. More >

Biotech Announces Encouraging HIV Vaccine Results
Source: Streetwise Reports  (5/23/18)
Ram Selvaraju, an analyst with H.C. Wainwright & Co., explained the recently released data from a study of one of this immunotherapy firm's therapeutics.
More >

Analyst: 'New CEO, Larger Sales Team and Greater SUI Focus Should Help Medical Device Growth'
Source: Streetwise Reports  (5/23/18)
Cowen analyst Dr. Joshua Jennings highlighted this medical device firm's Q1/18 developments and financial results. More >

Cancer in the Crosshairs: IMV Looks to Deliver Immunotherapy a New Way
Source: Streetwise Reports  (5/16/18)
In this interview with The Life Sciences Report, IMV Inc.'s CEO Fred Ors and Pierre Labbè, chief financial officer, describe the innovative immunotherapy platform technology that has attracted partnerships with big pharma, prompted reorganization of the company, and holds long-term promise for cancer patients. More >